Back

Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity and development of heart failure Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Berlinde von Kemp

University Hospital (UZ) Brussels, Brussels (Belgium)

7 More presentations in this session

Presentation thumbnail
Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Low clinical utility of global longitudinal strain in a real-world breast cancer population
Doctor L. Ruane (Brisbane, AU)
Abstract Slides Video
Presentation thumbnail
Angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan) in cancer therapy-related cardiac dysfunction: real-world experience from a nurse-led cardio-oncology clinic
Miss P. Reehal (London, GB)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, resource use, and diagnostic accuracy of natriuretic peptides in cancer patients presenting with acute dyspnea to the Emergency Department
Doctor P. Lopez Ayala (Basel, CH)
Abstract Slides Video
Presentation thumbnail
miRNAs profile as a signature for cardiovascular disease in long-term breast cancer female survivors: a pilot study
Doctor A. Greatti (Ferrara, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity and development of heart failure

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Is there an association of anthracyclines with HFrEF and/or HFpEF in patients treated for breast cancer or lymphoma after 30 years of follow-up? Insights from the Rochester epidemiology project
thumbnail
Congress Presentation
Characteristics and outcomes of patients with a history of cancer enrolled in our prospective HFpEF registry
thumbnail
Congress Presentation
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources